A Microneurography Study of NaV1.8 Inhibition in Healthy Adults

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

Key Inclusion Criteria:

• Body mass index (BMI) of 18.0 to 30.0 kilogram per meter square (kg/m^2)
• A total body weight of more than (>) 50 kg

Key Exclusion Criteria:

• History of febrile illness or other acute illness that has not fully resolved within 14 days before study drug dosing
• Any condition possibly affecting drug absorption
• Any dermatological (generalized) or autoimmune disease that may affect C-nociceptor excitability
• Participants with Type 1 or Type 2 diabetes mellitus
• Participants who have any 1 of the following criteria in the foot in which microneurography (MNG) will be performed:

• Injection of local anesthetics or steroids within 35 days prior to randomization.
• Unsuitable anatomy of the superficial peroneal nerve (i.e., nerve cannot be seen or palpated at the dorsum of the foot)
• Infection, disease (dermatologic or vascular), ongoing pain, or recent trauma or surgery that may affect study assessments Note: Participants must have 1 foot that does not meet any of the above criteria to be eligible.

Other protocol defined Inclusion/Exclusion criteria may apply.